Landscape Capital Management L.L.C. Sells 31,225 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Landscape Capital Management L.L.C. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 60.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,787 shares of the biopharmaceutical company’s stock after selling 31,225 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Gilead Sciences were worth $1,920,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Wescott Financial Advisory Group LLC increased its stake in shares of Gilead Sciences by 5.4% during the 4th quarter. Wescott Financial Advisory Group LLC now owns 3,553 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 182 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC increased its stake in shares of Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 216 shares in the last quarter. Pitcairn Co. boosted its holdings in Gilead Sciences by 4.0% in the 4th quarter. Pitcairn Co. now owns 6,845 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 265 shares during the period. Arete Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 11.5% in the fourth quarter. Arete Wealth Advisors LLC now owns 10,909 shares of the biopharmaceutical company’s stock worth $1,005,000 after acquiring an additional 1,125 shares during the period. Finally, Motley Fool Asset Management LLC boosted its holdings in shares of Gilead Sciences by 14.9% in the fourth quarter. Motley Fool Asset Management LLC now owns 67,103 shares of the biopharmaceutical company’s stock worth $6,198,000 after acquiring an additional 8,678 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on GILD. Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Royal Bank of Canada raised their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Bank of America raised their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $105.12.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 302,785 shares of company stock worth $30,503,250 in the last three months. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $107.25 on Friday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The stock has a market capitalization of $133.54 billion, a price-to-earnings ratio of 289.86, a PEG ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business’s fifty day moving average price is $107.30 and its 200-day moving average price is $95.80.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.